Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma
Open Access
- 13 May 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 9, 807622
Abstract
Background: Dysregulation of RNA-binding proteins (RBPs) in cancers is associated with immune and cancer development. Here, we aimed to profile immune-related RBPs in lung adenocarcinoma (LUAD) and construct an immune-related RBP signature (IRBPS) to predict the survival and response to immunotherapy.Methods: A correlation analysis was performed to establish a co-expression network of RBPs and immune-related genes (IRGs) to characterize immune-related RBPs in the TCGA–LUAD cohort (n = 497 cases). Then, a combination of the Random survival forest (RSF) and Cox regression analysis was performed to screen the RBPs and establish IRBPS. This was followed by independent validation of IRBPS in GSE72094 (n = 398 cases), GSE31210, (n = 226 cases), and GSE26939 (n = 114 cases). Differences between the low- and high-risk groups were compared in terms of gene mutations, tumor mutation burden, tumor-infiltrating lymphocytes, and biomarkers responsive to immunotherapy.Results: DDX56, CTSL, ZC3H12D, and PSMC5 were selected and used to construct IRBPS. The high-risk scores of patients had a significantly worse prognosis in both training and testing cohorts (p < 0.0001 and p < 0.05, respectively), and they tended to be older and have an advanced TNM stage. Furthermore, IRBPS was a prognostic factor independent of age, gender, smoking history, TNM stage, and EGFR mutation status (p = 0.002). In addition, high-risk scores of IRBPS were significantly correlated with tumor-infiltrating lymphocytes (p < 0.05). They also had a high level of PD-L1 protein expression (p < 0.01), number of neoantigens (p < 0.001), and TMB (p < 0.001), implying the possible prediction of IRBPS in the immunotherapy of LUAD.Conclusion: The currently established IRBPS encompassing immune-related RBPs might serve as a promising tool to predict survival, reflect the immune microenvironment, and predict the efficacy of immunotherapy among LUAD patients.Keywords
Funding Information
- Science and Technology Planning Project of Guangdong Province (201802020033)
This publication has 42 references indexed in Scilit:
- RNA binding proteins as regulators of immune cell biologyClinical and Experimental Immunology, 2015
- VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumorsJournal of Experimental Medicine, 2015
- Context-dependent control of alternative splicing by RNA-binding proteinsNature Reviews Genetics, 2014
- Non-small-cell lung cancers: a heterogeneous set of diseasesNature Reviews Cancer, 2014
- The putative tumor suppressor Zc3h12d modulates toll-like receptor signaling in macrophagesCellular Signalling, 2012
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2011
- Pre-mRNA Processing Reaches Back toTranscription and Ahead to TranslationCell, 2009
- mRNA Localization: Gene Expression in the Spatial DimensionCell, 2009
- Identification of a Novel Tumor Suppressor Gene p34 on Human Chromosome 6q25.1Cancer Research, 2007
- Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cellsCancer Cell, 2004